Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN) -- Ignore unavailable to you. Want to Upgrade?

To: Jonathan Schonsheck who wrote (3620)	5/17/1998 10:10:00 PM
From: Jonathan Schonsheck	Read Replies (1) \| Respond to of 4342

PRLN Stockholders' Meeting (continued . . ..) The first products which Paracelsian seeks to certify as BioFIT are St. John's Wort, Ginko, and Echinacea. ((An editorial comment: these are, of course, among the most popular nutraceuticals.)) As Paracelsian's scientists work with assays to validate structure and function claims, they will return to our library of Traditional Chinese Medicines, continuing the search for useful products. (In the course of using assays to certify the products of others, the value of our own library increases.) At this point, ten candidates for pharmaceutical development (as contrasted with dietary supplement development) have been identified. Efforts to market Ah-Immunoassay (for detecting dioxin and similar substances) continue apace. Japan, China and Eastern Europe are viewed as promising markets; the market potential is enormous. The Company is actively promoting the CDK1 Assay. It can determine whether a substance is carcinogenic (in certain ways) before a drug company spends vast sums of money researching it further. As this will save substantial research dollars, the market appears very significant.